elderly Burkitt lymphoma and intermediate Burkitt lymphoma/diffuse large B cell lymphoma
Conditions
Interventions
6-8 cycles of R-EPOCH are scheduled. The patients achieved CR after 4 cycles recieve total 6cycles, and the patients achieved PR after 4 cycles recieve total 8 cycles.
Sponsors
Clinical Hematology Study Group of National Hospital Organization(CHSG-NHO)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.pathological diagnosis: Burkitt lymphoma or intermediate Burkitt lymphoma/diffuse large B cell lymphoma 2.CD20 antigen positive 3.no prior therapy for lymphoma 4.lymphoma cells less than 5000/mm3 in peripheral blood 5.presence of mesurable lesions 6.age: 65-79 years old 7.PS(ECOG): 0-2 8.adequate organ funcitions 9.informed consented patients
Exclusion criteria
Exclusion criteria: 1.presence of active infeciton 2.presence of central nervous invasion 3.past history of glaucoma. 4.past history of severe drug allergy. 5.HIV Ab positive or HTLV-1 Ab positive. 6.HBsAg positive or HCV Ab positive. 7.severe cardiac disease 8.hepatic cirrhosis 9.uncontrollable diabetis melitus 10.patients with dialysis 11.lung fibrosis or interstitial pneumonitis 12.other active malignancies 13.pregnant or feeding female 14.severe mental disorder 15.judged for inappropriate with other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2 years progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| complete remission rate, 2 years over all survival, safety | — |
Countries
Japan
Contacts
Public ContactHirokazu Nagai
National Hospital Organization Nagoya Medical Center Clinical Research Center
Outcome results
None listed